Agnès Portron

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W. Pipe, Midori Shima, Michaela Lehle et al. · The Lancet Haematology · 2019 · 373 citations · Full text

Haven 4, Hematology, Non-randomised Phase 3 +2

Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist <scp>RG</scp> 7697 in people with type 2 diabetes mellitus

Christophe Schmitt, Agnès Portron, Shirin Jadidi et al. · Diabetes Obesity and Metabolism · 2017 · 73 citations

Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 agonist <scp>RG</scp> 7697 after single subcutaneous administration in healthy subjects

Agnès Portron, Shirin Jadidi, Neena Sarkar et al. · Diabetes Obesity and Metabolism · 2017 · 46 citations

A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers

Agnès Portron, Paul Jordan, Kristy Draper et al. · Clinical Therapeutics · 2019 · 43 citations

A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans

Dietmar Schwab, Agnès Portron, Zoe Backholer et al. · Clinical Pharmacokinetics · 2013 · 37 citations

Biochemistry, Medicine, Oral Administration +11